[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA200101106A1 - Фармацевтический комплекс - Google Patents

Фармацевтический комплекс

Info

Publication number
EA200101106A1
EA200101106A1 EA200101106A EA200101106A EA200101106A1 EA 200101106 A1 EA200101106 A1 EA 200101106A1 EA 200101106 A EA200101106 A EA 200101106A EA 200101106 A EA200101106 A EA 200101106A EA 200101106 A1 EA200101106 A1 EA 200101106A1
Authority
EA
Eurasian Patent Office
Prior art keywords
complex
pharmaceutical complex
sulfobutylether
eletriptan
cyclodextrin
Prior art date
Application number
EA200101106A
Other languages
English (en)
Other versions
EA003908B1 (ru
Inventor
Энн Биллотт
Original Assignee
Пфайзер Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Инк. filed Critical Пфайзер Инк.
Publication of EA200101106A1 publication Critical patent/EA200101106A1/ru
Publication of EA003908B1 publication Critical patent/EA003908B1/ru

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nanotechnology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Данное изобретение относится к комплексу элетриптана и сульфобутилэфир-бета-циклодекстрина или их фармацевтически приемлемой соли, к способу приготовления фармацевтических препаратов, включающих в себя такой комплекс, и к применению такого комплекса.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200101106A 1999-06-29 2000-06-02 Фармацевтический комплекс элетриптана и производного циклодекстрина EA003908B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9915231.6A GB9915231D0 (en) 1999-06-29 1999-06-29 Pharmaceutical complex
PCT/IB2000/000746 WO2001000243A1 (en) 1999-06-29 2000-06-02 Pharmaceutical complex

Publications (2)

Publication Number Publication Date
EA200101106A1 true EA200101106A1 (ru) 2002-06-27
EA003908B1 EA003908B1 (ru) 2003-10-30

Family

ID=10856302

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200101106A EA003908B1 (ru) 1999-06-29 2000-06-02 Фармацевтический комплекс элетриптана и производного циклодекстрина

Country Status (44)

Country Link
US (2) US6713461B1 (ru)
EP (1) EP1189640B1 (ru)
JP (2) JP4454900B2 (ru)
KR (1) KR20020015067A (ru)
CN (1) CN1198654C (ru)
AP (1) AP2001002369A0 (ru)
AR (1) AR033337A1 (ru)
AT (1) ATE290884T1 (ru)
AU (1) AU770169B2 (ru)
BG (1) BG106151A (ru)
BR (1) BR0011845A (ru)
CA (1) CA2376847C (ru)
CO (1) CO5170494A1 (ru)
CZ (1) CZ20014572A3 (ru)
DE (1) DE60018744T2 (ru)
DZ (1) DZ3320A1 (ru)
EA (1) EA003908B1 (ru)
EC (1) ECSP003551A (ru)
EE (1) EE200100697A (ru)
ES (1) ES2235879T3 (ru)
GB (1) GB9915231D0 (ru)
GE (1) GEP20043377B (ru)
GT (1) GT200000102A (ru)
HR (1) HRP20010951A2 (ru)
HU (1) HUP0201629A3 (ru)
IL (1) IL146341A0 (ru)
IS (1) IS6163A (ru)
MA (1) MA26801A1 (ru)
MX (1) MXPA01013274A (ru)
NO (1) NO20016430L (ru)
NZ (1) NZ515235A (ru)
OA (1) OA11964A (ru)
PA (1) PA8496801A1 (ru)
PE (1) PE20010346A1 (ru)
PL (1) PL352902A1 (ru)
SK (1) SK18932001A3 (ru)
SV (1) SV2002000112A (ru)
TN (1) TNSN00142A1 (ru)
TR (1) TR200103827T2 (ru)
UA (1) UA66932C2 (ru)
UY (1) UY26224A1 (ru)
WO (1) WO2001000243A1 (ru)
YU (1) YU87501A (ru)
ZA (1) ZA200110454B (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9915231D0 (en) * 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
EP1542668B1 (en) * 2002-08-20 2009-04-15 Bristol-Myers Squibb Company Aripiprazole complex formulation and method
GB0329918D0 (en) * 2003-12-24 2004-01-28 West Pharm Serv Drug Res Ltd Intranasal compositions
CN1296391C (zh) * 2004-03-04 2007-01-24 中国人民解放军第二军医大学 氟代羧烷基环糊精醚类化合物及其制备方法和应用
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
CN101957330B (zh) * 2010-06-12 2013-10-09 南京巨环医药科技开发有限公司 磺丁基倍他环糊精含量的测定方法
WO2017122161A1 (en) * 2016-01-15 2017-07-20 Cadila Healthcare Limited An intranasal composition comprising 5ht1b/1d receptor agonists
WO2019143925A1 (en) * 2018-01-22 2019-07-25 Insys Development Company, Inc. Liquid rizatriptan compositions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
HU210921B (en) 1990-03-28 1995-09-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing inclusion complexes of n-ethoxycarbonyl-3-morpholino-sydnonimine formed with cyclodextrines and pharmaceutical compositions containing them
HU211648A9 (en) 1990-03-28 1995-12-28 Chinoin Gyogyszer Es Vegyeszet Inclusion complexes of 3-morpholino-sydnonimine or its salts or its tautomer isomer, process for the preparation thereof, and pharmaceutical compositions containing the same
DK0592438T5 (da) 1990-10-15 1999-12-06 Pfizer Inc. Indolderivater
RU2143896C1 (ru) 1993-03-05 2000-01-10 Хексаль Аг Кристаллический комплекс циклодекстрина с гидрохлоридом ранитидина, способ его получения и содержащие его фармацевтические составы
MX9504664A (es) 1994-03-07 1997-05-31 Dow Chemical Co Conjugados de dendrimeros bioactivos y/o dirigidos.
GB9417310D0 (en) 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
AU712546B2 (en) 1996-07-11 1999-11-11 Farmarc Nederland Bv Inclusion complex containing indole selective serotonin agonist
US5998462A (en) 1996-12-16 1999-12-07 Allelix Biopharmaceuticals Inc. 5-alkyl indole compounds
GB9704498D0 (en) 1997-03-05 1997-04-23 Glaxo Wellcome Spa Chemical compound
PT999841E (pt) 1997-07-03 2002-02-28 Pfizer Composicoes farmaceuticas contendo hemissulfato de eletriptano
GB9816556D0 (en) * 1998-07-30 1998-09-30 Pfizer Ltd Therapy
GB9915231D0 (en) * 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex

Also Published As

Publication number Publication date
AP2001002369A0 (en) 2001-12-31
PA8496801A1 (es) 2002-02-21
HRP20010951A2 (en) 2005-04-30
SK18932001A3 (sk) 2002-09-10
CA2376847C (en) 2007-09-25
UA66932C2 (en) 2004-06-15
NO20016430D0 (no) 2001-12-28
BG106151A (en) 2002-05-31
SV2002000112A (es) 2002-02-05
CN1198654C (zh) 2005-04-27
AR033337A1 (es) 2003-12-17
EA003908B1 (ru) 2003-10-30
IS6163A (is) 2001-11-16
KR20020015067A (ko) 2002-02-27
AU4774100A (en) 2001-01-31
EP1189640B1 (en) 2005-03-16
IL146341A0 (en) 2002-07-25
OA11964A (en) 2006-04-17
HUP0201629A2 (hu) 2003-03-28
TR200103827T2 (tr) 2002-05-21
TNSN00142A1 (fr) 2005-11-10
WO2001000243A1 (en) 2001-01-04
US20040186076A1 (en) 2004-09-23
CZ20014572A3 (cs) 2002-08-14
ZA200110454B (en) 2002-12-20
JP2003503364A (ja) 2003-01-28
GB9915231D0 (en) 1999-09-01
DE60018744T2 (de) 2006-05-18
PE20010346A1 (es) 2001-03-26
CN1359303A (zh) 2002-07-17
YU87501A (sh) 2004-05-12
MA26801A1 (fr) 2004-12-20
ES2235879T3 (es) 2005-07-16
EP1189640A1 (en) 2002-03-27
JP2006257091A (ja) 2006-09-28
US6713461B1 (en) 2004-03-30
ATE290884T1 (de) 2005-04-15
CA2376847A1 (en) 2001-01-04
JP4454900B2 (ja) 2010-04-21
AU770169B2 (en) 2004-02-12
DE60018744D1 (de) 2005-04-21
BR0011845A (pt) 2002-03-05
NZ515235A (en) 2003-08-29
GT200000102A (es) 2001-12-14
DZ3320A1 (fr) 2001-01-04
UY26224A1 (es) 2001-01-31
GEP20043377B (en) 2004-04-13
HUP0201629A3 (en) 2003-11-28
ECSP003551A (es) 2002-01-25
PL352902A1 (en) 2003-09-22
NO20016430L (no) 2002-02-26
MXPA01013274A (es) 2002-06-04
EE200100697A (et) 2003-02-17
CO5170494A1 (es) 2002-06-27

Similar Documents

Publication Publication Date Title
EA199800946A1 (ru) Концентрированный препарат антител
DE69925133D1 (de) Pyrrolobenzodiazepine
ATE425253T1 (de) Tribonektine
EA200101156A1 (ru) ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НОВОГО ТИПА НА ОСНОВЕ ОБЛАДАЮЩИХ ХОЛИНЕРГИЧЕСКИМ ДЕЙСТВИЕМ СОЕДИНЕНИЙ И β-МИМЕТИКОВ
EA200200571A1 (ru) Новая композиция и ее применение
EA200400241A1 (ru) Направленные к мишени мультимерные контрастные вещества, основанные на пептидах
EA199900561A1 (ru) Производные сульфонамида, способ их получения и их использование в качестве лекарственных средств
EA200100688A1 (ru) АЗОТСОДЕРЖАЩИЕ ГЕТЕРОБИЦИКЛЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА Xa
EA200300459A1 (ru) Новые, применяемые в качестве медикаментов антихолинергические средства, а также способ их получения
EA200301223A1 (ru) Лекарственные формы окскарбазепина
EA200200119A1 (ru) β-КАРБОЛИНОВЫЕ ЛЕКАРСТВЕННЫЕ ПРОДУКТЫ
EA200500388A1 (ru) Способ получения сухих порошковых композиций для ингаляции
EA199900331A1 (ru) Препарат из покрытых частиц
EA199700160A1 (ru) Производные индола в качестве антагонистов eaa
EA200201138A1 (ru) Пептид, модулирующий рецептор тромбопоэтина
EA199800230A1 (ru) Тетрагидрохинолины в качестве антагонистов nmda (n-метил-d-аспарагиновой кислоты)
EA200300392A1 (ru) Производные пиперазина с мостиковой связью
EA200101106A1 (ru) Фармацевтический комплекс
SE8904298D0 (sv) New compounds
EA200000322A1 (ru) Способ синтеза производных хинолина
EE200300129A (et) Distamütsiini alfa-halogenoakrüloüülderivaadi kasutamine
EA199901116A1 (ru) Композиция, включающая 5-[4-[2-(n-метил-n-2-пиридил)-амино)этокси]бензил]тиазолидин-2,4-дион
EA199900750A1 (ru) Водная фармацевтическая композиция, включающая активный ингредиент, в высшей степени нерастворимый в воде
EA200101150A1 (ru) Раствор прукалоприда для перорального применения
EA200100984A1 (ru) Новые кристаллические формы макролидного антибиотика

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU